Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy

Abstract

Pregnant women are particularly susceptible to influenza-related morbidity and mortality and have historically been over-represented among patients with influenza, requiring hospitalization and intensive care unit admission. This has been observed during both nonpandemic and pandemic influenza seasons. During the H1N1 influenza pandemic of 2009-2010, pregnant women again had an increased likelihood of hospital or intensive care unit admission, and many deaths were documented. One identified risk factor for more severe disease was a delay in the initiation of antiviral medications. Vaccination is currently the most effective method for preventing severe influenza and its sequelae, and antiviral medications are used as an important adjunct to vaccination. Knowledge among pregnant women regarding influenza vaccine recommendations is poor, but by improving knowledge and understanding, vaccine rates can be increased. Although there are no published data examining knowledge regarding antiviral medications, one can hypothesize that knowledge is similarly low. In the current era, the appropriate use of vaccination and antiviral medications is the best defense against complications of influenza among pregnant women, and optimizing knowledge about these strategies among providers and patients alike is of paramount importance.